Fatostatin hydrobromide
SIGMA/F8932 - ≥98% (HPLC), powder
Synonym: 25B11 hydrobromide; 4-
CAS Number: 298197-04-3
Empirical Formula (Hill Notation): C18H18N2S·HBr
Molecular Weight: 375.33
MDL Number: MFCD00760867
Linear Formula: C18H18N2S·HBr
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | light yellow to yellow |
| form | powder |
| InChI | 1S/C18H18N2S.BrH/c1-3-4-1 |
| InChI key | RJCFNQZVFUMORB-UHFFFAOYSA |
| Quality Level | 100 ![]() |
| SMILES string | [s]1c(nc(c1)c3ccc(cc3)C)c |
| solubility | DMSO: ≥10 mg/mL |
| storage condition | desiccated |
| storage temp. | 2-8°C |
| Application: | Fatostatin hydrobromide has been used: • to study its anti-cancer activity and effects on mitotic microtubule spindle • to study its effects on stomatal development • to prevent SREBP cleavage-activating protein (SCAP)-mediated escort of sterol regulatory element-binding proteins (SREBPs) |
| Biochem/physiol Actions: | Fatostatin hydrobromide is an SREBP inhibitor. |
| Biochem/physiol Actions: | Fatostatin hydrobromide is an SREBP inhibitor. Fatostatin hydrobromide inhibits fat production and lowers glucose levels in mice by inhibiting SREBP (Sterol Regulatory Element Binding Proteins). |
| General description: | Fatostatin is a non-sterol diarylthiazole derivative. It prevents insulin-induced adipogenesis and lowers the amounts of fatty acid, triglyceride and low-density lipoprotein. Fatostatin has anti tumor and antimitotic properties. |
| Packaging: | 5, 25 mg in glass bottle |
| Hazard Codes | Xn |
| Risk Statements | 22 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 1 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |

